Emblem, Kyrre E
Jain, Rakesh K
Article History
First Online: 8 November 2016
Competing interests
: K.E.E. has no conflicts of interest. E.K.J. has received consultant fees from Enlight, Ophthotech, SPARC and SynDevRx, owns equity in Enlight, Ophthotech, SynDevRx and XTuit, and serves on the Board of Directors of XTuit and the Boards of Trustees of Tekla Healthcare Investors, Tekla Life Sciences Investors, Tekla Healthcare Opportunities Fund and Tekla World Healthcare Fund. No funding or reagents from these companies were used in this study.